Concepedia

Adriana Zupa-Fernandez

AZ

Statistics

Publications

8

Citations

1.1K

H-Index

8

Active since

2015

Affiliations

Bristol-Myers Squibb (United States)(Current)

Bristol-Myers Squibb (Germany)

Bristol-Myers Squibb (Sweden)

Adriana Zupa-Fernandez is an author at Bristol-Myers Squibb (United States) specializing in pharmacology, medicinal chemistry, and life sciences.

ORCID

Publications per year

2015–2020

8

Publications

8

Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165

Stephen T. Wrobleski, Ryan Moslin, Shuqun Lin et al. · Journal of Medicinal Chemistry · 2019 · 369 citations · Full text

, , +15

Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain

James R. Burke, Lihong Cheng, Kathleen M. Gillooly et al. · Science Translational Medicine · 2019 · 282 citations

, , +14

Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain

John S. Tokarski, Adriana Zupa-Fernandez, Jeffrey Tredup et al. · Journal of Biological Chemistry · 2015 · 116 citations · Full text

, , +17

Identification of <i>N</i>-Methyl Nicotinamide and <i>N</i>-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2)

Ryan Moslin, Yanlei Zhang, Stephen T. Wrobleski et al. · Journal of Medicinal Chemistry · 2019 · 92 citations · Full text

, , +17

Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2

Chunjian Liu, James C. Lin, Charles M. Langevine et al. · Journal of Medicinal Chemistry · 2020 · 87 citations · Full text

, , +17

1–5 of 8